Spruce biosciences reports baseline characteristics from cahmelia-203 and cahmelia-204 studies in adult classic cah

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported baseline characteristics of patients enrolled in the cahmelia-203 and cahmelia-204 clinical studies of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (cah). “the baseline characteristics of patients enr.
SPRB Ratings Summary
SPRB Quant Ranking